Sprint Bioscience (SPRINT) Life Science Summit 2025 summary

Company overview and innovation strategy

• Focuses on early-stage drug discovery and preclinical development, building an innovation engine over 16 years.

• Operates as a non-GXP entity, partnering early rather than advancing programs into clinical phases.

• Specializes in immune oncology, tumor metabolism, and tumor microenvironment using fragment-based drug design.

• Utilizes a proprietary fragment library and advanced protein science to accelerate target screening.

• Employs structural biology and computational chemistry for efficient molecule optimization.

Business model and partnerships

• Maintains a cost-efficient, early-phase focus, handing off clinical development to partners.

• Has executed six license agreements, generating milestones and royalties.

• Explores diversification through asset spinouts and strategic collaborations.

• Attracts interest from venture capital and industry partners for both assets and expertise.

• Strategic collaborations provide short- to mid-term revenue while pursuing larger licensing deals.

Pipeline and portfolio management

• Maintains a broad pipeline with five ongoing internal development programs.

• Recently partnered with a Singapore entity for further development of a MASH and inflammation program, sharing future revenues.

• Holds additional undisclosed early-stage programs, focusing on maximizing current portfolio value.

• Broader portfolio increases chances of success and partnership opportunities.

• Continues to see growing scientific and industry interest in its assets.